Abstract:PURPOSE To explore and evaluate the protective effect of erythropoietin (EPO) on retinal cells of chemically induced diabetic rats after EPO was injected intravitreally at the onset of diabetes. METHODS Diabetes was induced in Sprague-Dawley rats by intraperitoneal injection of streptozotocin (STZ). At the onset of diabetes, a single intravitreal injection of EPO (0.05-200 ng/eye) was performed. In the following 6 weeks, the blood retinal barrier (BRB) was evaluated by Evans blue permeation (EBP). Retinal cell death in different layers was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The retinal thickness and cell counts were examined at the light microscopic level. Electron microscopy (EM) was used to scrutinize retinal vascular and neuronal injury. Neurosensory retinas of normal and diabetic rats were used as the sources of reverse transcription-polymerase chain reaction (RT-PCR) and Western blot for the detection of EPO, EPO receptor (EpoR), and products of the extracellular signal-regulated kinase (ERK) and the signal transducers and activators of transcription 5 (STAT5) pathways. The distribution of EpoR in retinal layers was demonstrated by immunohistochemistry (IHC). RESULTS In the diabetic rats, BRB breakdown was detected soon after the onset of diabetes, peaked at 2 weeks, and reached a plateau at 2 to 4 weeks. The number of TUNEL-positive cells increased in the neurosensory retina, especially, the outer nuclear layer (ONL) at 1 week after diabetes onset and reached a peak at 4 to 6 weeks. The retinal thickness and the number of cells in the ONL were reduced significantly. EM observations demonstrated vascular and photoreceptor cell death starting soon after the onset of diabetes. All these changes were largely prevented by EPO treatment. Upregulation of EpoR in the neurosensory retina was detected at both the transcriptional and protein levels 4 to 8 weeks after the onset of diabetes, whereas, the endogenous EPO levels of neurosensory retinas were essentially unchanged during the same period observed. In EPO-treated diabetic groups, EpoR expression remained at upregulated levels. Within 2 weeks of the onset of diabetes, activation of the ERK but not the STAT5 pathway was detected in the diabetic retina treated with EPO. CONCLUSIONS These data demonstrate that apoptosis is an major contributor to neuronal cell death in the early course of diabetic retinopathy (DR). The upregulation of EpoR may be a compensatory response of retinal cells and tissue to diabetic stresses. The EPO/EpoR system as a maintenance-survival mechanism of retinal neurons responds to the insults of early diabetes other than ischemia. The protective function of EPO/EpoR at the least acts through the EpoR-mediated ERK pathway. Exogenous EPO administration by intravitreal injection in early diabetes may prevent retinal cell death and protect the BRB function. Therefore, this is a novel approach for treatment of early DR.

Anti-Vegf Effects of Intravitreal Erythropoietin in Early Diabetic Retinopathy

Intravitreal Injection of Erythropoietin Protects Both Retinal Vascular and Neuronal Cells in Early Diabetes

Erythropoietin Maintains VE-cadherin Expression and Barrier Function in Experimental Diabetic Retinopathy Via Inhibiting VEGF/VEGFR2/Src Signaling Pathway

Erythropoietin Protects Outer Blood-Retinal Barrier in Experimental Diabetic Retinopathy by Up-Regulating ZO-1 and Occludin

Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy

EPO Attenuates Inflammatory Cytokines by Muller Cells in Diabetic Retinopathy.

Erythropoietin Therapy for Early Diabetic Retinopathy Through Its Protective Effects on Retinal Pericytes.

Differential Gene Expression Pattern of Diabetic Rat Retinas after Intravitreal Injection of Erythropoietin

Subretinal Delivery of AAV2-Mediated Human Erythropoietin Gene is Protective and Safe in Experimental Diabetic Retinopathy

Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina

Carbamylated Erythropoietin Mediates Retinal Neuroprotection in Streptozotocin-Induced Early-Stage Diabetic Rats

Erythropoietin promotes retinal angiogenesis in a mouse model.

Erythropoietin Exerts a Neuroprotective Function Against Glutamate Neurotoxicity in Experimental Diabetic Retina.

Safety and Efficacy of Intravitreal Injection of Recombinant Erythropoietin for Protection of Photoreceptor Cells in a Rat Model of Retinal Detachment

Erythropoietin Protects Retinal Cells In Diabetic Rats Through Upregulating Znt8 Via Activating Erk Pathway And Inhibiting Hif-1 Alpha Expression

Research progress in molecular mechanism of erythropoietin and ischemic retinal disease

VEGF As a Direct Functional Regulator of Photoreceptors and Contributing Factor to Diabetes-Induced Alteration of Photoreceptor Function

Administration of pigment epithelium-derived factor delivered by adeno-associated virus inhibits blood-retinal barrier breakdown in diabetic rats.

Effects of vascular endothelial growth factor antisense oligonucleotide combined with angiopoietin-1 on retinal vascular leakage and neovascularization in diabetic retinopathy rats

Enzyme-induced Vitreolysis Can Alleviate the Progression of Diabetic Retinopathy Through the HIF-1α Pathway.

Effects of erythropoietin on myocardial vascular endothelial growth factor expression and cardiac dysfunction in diabetic rats